• Patient-Derived Gastric Cancer Assembloids

  2026-10-01

  The reference study develops patient-specific gastric cancer assembloids by combining matched tumor organoids with tumor-derived stromal subpopulations. Its findings show that stromal composition alters gene expression and drug sensitivity, creating a more informative model for tumor–microenvironment research and personalized treatment studies.

• RepSox for iPSC Differentiation Workflows

  2026-09-30

  RepSox provides a selective ALK5 inhibition arm for studying TGF-β control of reprogramming, differentiation, and megakaryocyte maturation. This practical guide connects product handling with an optimized hiPSC-to-platelet workflow while separating published benchmarks from conditions that require local validation.

• HDAC Inhibitors Repress NUT Function in NUT Carcinoma

  2026-09-30

  A dCas9-based transcriptional screen identified structurally diverse histone deacetylase inhibitors as repressors of BRD4-NUT activity in NUT carcinoma. The study links HDAC inhibition to loss of megadomain-associated oncogene expression, induction of differentiation programs, and improved tumor control when combined with bromodomain inhibition.

• Sulfo-NHS-SS-Biotin: Practical Labeling Guide

  2026-09-29

  Sulfo-NHS-SS-Biotin is a water-compatible, amine-reactive reagent for labeling lysine side chains and N-terminal amines before avidin/streptavidin affinity chromatography. Its disulfide spacer permits reduction-based release of the biotin label, while its sulfo-NHS ester requires fresh preparation and immediate use. It is appropriate for surface-accessible or purified proteins, but not for intact-cell intracellular labeling without a separate permeabilization strategy.

• Dasatinib: A Mechanistic Assay Design Guide

  2026-09-29

  Dasatinib and BMS-354825 are powerful tools for separating proximal kinase effects from complex cancer phenotypes. This guide develops a causal assay framework linking Src, Bcr-Abl, FAK phosphorylation, EMT, and the SNAI1–PIK3R2/p-EphA2 axis.

• RBMS1 Loss Enables PD-L1 Blockade in TNBC

  2026-09-28

  A 2022 study identified the RNA-binding protein RBMS1 as a post-transcriptional regulator of PD-L1 stability in immune-cold triple-negative breast cancer. By linking RBMS1 depletion to reduced B4GALT1 expression, impaired PD-L1 glycosylation, and stronger cytotoxic T-cell activity, the work provides a mechanistic rationale for improving checkpoint-based and CAR-T strategies.

• Beyond D2: A Translational Strategy for Trifluoperazine 2HCl

  2026-09-28

  A mechanistic and translational framework for using Trifluoperazine 2HCl to study dopamine D2 receptor signaling while separating target-linked effects from broader cellular responses.

• RRP Restores Lipid Balance in Hepatic Ischemia-Reperfusion

  2026-09-27

  This study links Radix Rehmanniae Praeparata (RRP) protection against hepatic ischemia-reperfusion injury to coordinated changes in cholesterol synthesis and efflux. In mouse and hepatocyte models, RRP activated AMPK-associated signaling, restrained SREBP2 processing, and promoted LXRα activity, providing a mechanistic framework for investigating lipid dysregulation in liver injury.

• Crizotinib Hydrochloride in Tumor Assembloids

  2026-09-26

  Patient-derived assembloids make tumor–stroma effects visible in drug response. This article explores how Crizotinib hydrochloride can support carefully controlled studies of ALK, c-Met, and ROS1 signaling in these more representative cancer models—without assuming that every tumor depends on those kinases.

• BMN 673 in HCC: Splicing and PARP Response

  2026-09-25

  BMN 673 (Talazoparib) is a potent PARP1/2 inhibitor, but response in hepatocellular carcinoma may depend on more than conventional BRCA status. This article examines how SmD2-regulated splicing could inform PARP-inhibitor assay design—and clarifies what remains untested for talazoparib.

• MG-262 and Muscle Proteostasis: A Translational Lens

  2026-09-25

  A translational perspective on using MG-262 to interrogate proteasome function alongside new findings on chaperone-mediated autophagy, muscle aging, and experimental design.

• Ibrutinib (PCI-32765): Practical BTK Assay Workflows

  2026-09-24

  Use Ibrutinib (PCI-32765) to test how BTK inhibition alters B-cell receptor responses and chronic lymphocytic leukemia cell survival. This guide pairs practical dose–response and signaling workflows with a clear boundary: findings from ATRX-deficient glioma studies can inform screening design, but do not establish a role for Ibrutinib in glioma.

• Anlotinib hydrochloride for Angiogenesis Assays

  2026-09-24

  Use Anlotinib hydrochloride to connect receptor-level target engagement with endothelial migration and tube-formation readouts. This workflow highlights how to distinguish multi-pathway anti-angiogenic effects from nonspecific cell injury, with practical starting conditions and troubleshooting guidance for cancer research.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-23

  This study introduces patient-derived gastric cancer assembloids that combine tumor organoids with stromal cell populations from the same tumor. The model captures microenvironment-associated gene-expression changes and reveals that stromal context can alter drug sensitivity, making it a useful platform for investigating tumor–stroma interactions and patient-specific treatment responses.

• BRCA2, PARP1 Retention, and RAD51 Filament Protection

  2026-09-23

  The reference study identifies a direct mechanism linking PARP inhibition to BRCA2-dependent homologous recombination: PARP1 retention on resected DNA destabilizes RAD51 filaments, whereas full-length BRCA2 prevents this interference. Biochemical, single-molecule, and cellular imaging experiments connect this mechanism to DNA repair deficiency targeting and clarify why BRCA2 status can influence responses to PARP inhibitors.

7966 records 1/532 page Next 12345 下5页 Last page